Last reviewed · How we verify
SOBI003
At a glance
| Generic name | SOBI003 |
|---|---|
| Also known as | Modified recombinant human sulphamidase |
| Sponsor | Swedish Orphan Biovitrum |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Vomiting
- Urticaria
- Gastroenteritis
- Pyrexia
- Iron deficiency anaemia
- Tachycardia
- Medical device site haemorrhage
- Conjunctivitis
- Viral infection
- Vascular access site occlusion
- Tremor
Key clinical trials
- A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients (PHASE1, PHASE2)
- A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOBI003 CI brief — competitive landscape report
- SOBI003 updates RSS · CI watch RSS
- Swedish Orphan Biovitrum portfolio CI